103,108 Shares in Bath & Body Works, Inc. (NYSE:BBWI) Purchased by Trexquant Investment LP

Trexquant Investment LP purchased a new stake in Bath & Body Works, Inc. (NYSE:BBWI) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 103,108 shares of the company’s stock, valued at approximately $4,450,000.

Several other large investors have also recently added to or reduced their stakes in BBWI. Denali Advisors LLC acquired a new position in shares of Bath & Body Works during the fourth quarter worth approximately $27,000. GAMMA Investing LLC acquired a new position in Bath & Body Works during the 4th quarter worth $27,000. Front Row Advisors LLC bought a new position in Bath & Body Works in the 3rd quarter valued at $25,000. Trust Co. of Vermont acquired a new stake in shares of Bath & Body Works in the 3rd quarter valued at $27,000. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in shares of Bath & Body Works during the fourth quarter worth $35,000. 95.14% of the stock is owned by institutional investors.

Insider Activity at Bath & Body Works

In other Bath & Body Works news, insider Thomas E. Mazurek sold 4,285 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $48.89, for a total transaction of $209,493.65. Following the sale, the insider now owns 45,992 shares of the company’s stock, valued at $2,248,548.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is currently owned by company insiders.

Bath & Body Works Price Performance

Shares of NYSE:BBWI opened at $48.70 on Thursday. Bath & Body Works, Inc. has a 1 year low of $27.30 and a 1 year high of $50.82. The stock has a market capitalization of $10.89 billion, a price-to-earnings ratio of 12.65, a price-to-earnings-growth ratio of 1.61 and a beta of 1.89. The company’s 50 day simple moving average is $46.85 and its 200 day simple moving average is $42.79.

Bath & Body Works (NYSE:BBWI) last issued its quarterly earnings data on Thursday, February 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.85 by $0.21. Bath & Body Works had a net margin of 11.82% and a negative return on equity of 37.01%. The business had revenue of $2.91 billion during the quarter, compared to the consensus estimate of $2.84 billion. During the same quarter in the prior year, the firm earned $1.86 EPS. The firm’s revenue was up .8% compared to the same quarter last year. As a group, analysts anticipate that Bath & Body Works, Inc. will post 3.33 EPS for the current fiscal year.

Bath & Body Works Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 21st. Stockholders of record on Friday, June 7th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, June 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.64%. Bath & Body Works’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BBWI shares. UBS Group increased their price target on shares of Bath & Body Works from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, March 4th. BMO Capital Markets lifted their price target on shares of Bath & Body Works from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. TD Cowen upped their price objective on shares of Bath & Body Works from $35.00 to $55.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. upgraded Bath & Body Works from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $40.00 to $53.00 in a report on Friday, May 17th. Finally, Wells Fargo & Company increased their price target on Bath & Body Works from $42.00 to $48.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bath & Body Works has a consensus rating of “Hold” and an average target price of $47.57.

Bath & Body Works Profile

Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.